NCT01279096 2026-04-22
Vandevol
University Hospital, Lille
Phase 1 Completed
Clinical Trials
6,130 trialsNCT03009240 2026-04-22
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia
City of Hope Medical Center
Phase 1 Completed
NCT05101551 2026-04-22
PARPAML
Stanford University
Phase 1 Recruiting
NCT06599762 2026-04-22
MYELO-CAN:TXA
University of Manitoba
Phase 2 Recruiting
NCT06839053 2026-04-22
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT07099443 2026-04-22
REBELLE
Nantes University Hospital
Phase NA Recruiting
NCT07133074 2026-04-22
RENEW-IN
University of Pennsylvania
Phase NA Recruiting
NCT07320235 2026-04-22
IMAGINE
Icahn School of Medicine at Mount Sinai
Phase 1 Recruiting
NCT07528417 2026-04-22
MYELO-CAN:ABX
University of Manitoba
Phase 2 Not yet recruiting
NCT01853358 2026-04-21
DLI-NK
Institut Paoli-Calmettes
Phase 1 Completed
NCT02553447 2026-04-21
Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency
University of Nebraska
Phase NA Completed
NCT03188874 2026-04-21
Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
Technische Universität Dresden
Recruiting
NCT03919240 2026-04-21
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
The First Affiliated Hospital of Soochow University
Phase 1/2 Recruiting
NCT04628026 2026-04-21
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
University of Ulm
Phase 3 Recruiting
NCT05646576 2026-04-21
PEACE
Massachusetts General Hospital
Phase NA Recruiting
NCT05858593 2026-04-21
Positive Youth Development in the Metaverse
University of Georgia
Phase NA Completed
NCT05952804 2026-04-21
IVIG for Infection Prevention After CAR-T-Cell Therapy
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT07513129 2026-04-21
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT07541326 2026-04-21
COMPLHEMATO
University Hospital, Limoges
Phase NA Not yet recruiting
NCT07541755 2026-04-21
PD1-VEN-CAG
Fujian Medical University Union Hospital
Phase 3 Active not recruiting
NCT02041416 2026-04-20
Technology to Assess Vulnerable Older Adults With Cancer and Their Caregivers
City of Hope Medical Center
Active not recruiting
NCT03094026 2026-04-20
cTAG
University of Alabama at Birmingham
Phase NA Recruiting
NCT04625413 2026-04-20
UR-GOAL 1
University of Rochester
Phase NA Completed
NCT05222984 2026-04-20
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax
City of Hope Medical Center
Phase 1 Active not recruiting
NCT05519579 2026-04-20
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
Northside Hospital, Inc.
Phase 2 Recruiting
NCT05848687 2026-04-20
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Stanford University
Phase 1/2 Recruiting
NCT05909059 2026-04-20
CAR T-cell Therapy in Patients With Renal Dysfunction
Northside Hospital, Inc.
Phase 2 Recruiting
NCT06859008 2026-04-20
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Recruiting
NCT07194980 2026-04-20
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Not yet recruiting
NCT07538401 2026-04-20
ASCiminib, With or Without Dasatinib Combination, as a 2nd-Line Therapy to ADVANCE the Treatment for Chronic Myelogenous Leukemia in Chronic Phase (ASC2ADVANCE)
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT07539779 2026-04-20
Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis
Nanfang Hospital, Southern Medical University
Phase 2/3 Not yet recruiting
NCT02390635 2026-04-17
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT03586609 2026-04-17
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04744116 2026-04-17
Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT04797767 2026-04-17
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
University of Washington
Phase 1/2 Recruiting
NCT04996160 2026-04-17
Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia
Stanford University
Phase 1 Completed
NCT05177211 2026-04-17
Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT05282459 2026-04-17
Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
Stanford University
Phase 1/2 Completed
NCT05983965 2026-04-17
Study of Tazemetostat in Lymphoid Malignancies
University of Alabama at Birmingham
Phase 1 Terminated
NCT06587100 2026-04-17
WATCH
University of California, San Francisco
Recruiting
NCT07302776 2026-04-17
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
Stanford University
Phase 1 Not yet recruiting
NCT07537257 2026-04-17
VEN+IDAC vs IDAC in AML
Guangdong Second Provincial General Hospital
Phase 2/3 Enrolling by invitation
NCT07537738 2026-04-17
MLL-LSC
Peking University People's Hospital
Recruiting
NCT00466531 2026-04-16
Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT00816114 2026-04-16
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
M.D. Anderson Cancer Center
Recruiting
NCT02131584 2026-04-16
Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03418038 2026-04-16
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Phase 2 Recruiting
NCT04140487 2026-04-16
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04493138 2026-04-16
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04552288 2026-04-16
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting